Arcus backs TIGIT combo by offering glimpse at positive data from axed trial

Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the approach forward in a different lung cancer setting. Gilead helped ...